Mural Oncology PLC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Mural Oncology plc has completed its acquisition by XOMA Royalty Corporation subsidiary, XRA 5 Corp., with shareholders receiving $2.035 per share in cash.
Mural Oncology plc shareholders overwhelmingly approved the proposed acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, paving the way for completion in Q4 2025.
Mural Oncology plc has entered into a definitive agreement to be acquired by XOMA Royalty Corporation for a cash consideration of $2.035 to $2.24 per share, following Mural's decision to discontinue all clinical development.
Mural Oncology reported a wider net loss in Q2 2025, driven by restructuring charges, as it continues to explore strategic alternatives after discontinuing all clinical development programs.
Mural Oncology plc announced the successful re-election of all six director nominees and the ratification of PricewaterhouseCoopers LLP as its independent auditor at its 2025 Annual General Meeting.
Mural Oncology discontinues clinical development of nemvaleukin alfa, reduces workforce by 90%, and explores strategic alternatives to maximize shareholder value.
Mural Oncology discontinues the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with pembrolizumab for platinum-resistant ovarian cancer due to failure to achieve statistically significant improvement in overall survival.
Mural Oncology has entered into an agreement with Jefferies LLC to sell up to $75 million of its ordinary shares through an at-the-market offering.
Mural Oncology reports financial results for Q4 and year-end 2024, highlighting upcoming clinical milestones and extending its cash runway into Q1 2026 through operational efficiencies.
Mural Oncology anticipates key data readouts for its lead candidate, nemvaleukin, in late-stage trials for ovarian cancer and mucosal melanoma, and has extended its cash runway into Q1 2026.
Mural Oncology reported its third quarter 2024 financial results and provided updates on its clinical pipeline, including key data readouts expected in 2025.
Mural Oncology's Investor Day provided updates on late-stage clinical trials for nemvaleukin and plans for their IL-18 program, with key data readouts expected in 2025.
Mural Oncology has appointed Sachiyo Minegishi to its Board of Directors, where she will also serve as the Chair of the Audit Committee.
Mural Oncology announced its second quarter 2024 financial results, provided an update on its pipeline progress, and reaffirmed its cash runway guidance into Q4 2025.
Dr. Susan Altschuller has resigned from Mural Oncology's Board of Directors, effective September 1, 2024, with no indication of disagreement with the company.
Mural Oncology has appointed George Golumbeski, Ph.D., as an independent director to its Board, effective July 30, 2024.
Mural Oncology held its 2024 annual general meeting on May 30, 2024, where shareholders voted on the election of directors and the ratification of the independent auditor.
Mural Oncology announced its first quarter 2024 financial results and provided a business update, highlighting progress in clinical trials and preclinical programs.
Mural Oncology reported its 2023 financial results, highlighted progress in its clinical trials, and provided an update on its pipeline, including a new dosing regimen for its lead candidate, nemvaleukin.